Objective  To compare the efficacy and safety of original and "drug volume-based pur-chasing" atorvastatin in patients with acute coronary syndrome.

Methods  The data of patients after acute coronary syndrome treated with original drugs (manufactured by Pifizer Inc. Lipitor group) and "drug volume-based purchasing" drugs (manufactured by Lepu Pharmaceuticals, Youliping group) from April 2020 to March 2021 were analyzed retrospectively. The standard rates of low-density lipoprotein-cholesterol (LDL-C), changes of blood fat profile and adverse events after treatment for 4-6 weeks were used as evaluation indexes.

Results  73 effective patients were included, with 37 patients in Lipitor group and 36 patients in Youliping group. The standard rate of LDL-C in Lipitor group was 43.2%, that in Youliping group was 50.0%, and there was no significant difference between the two groups (P>0.05). The blood lipid levels of patients in both groups after treatment were sig-nificantly improved compared with those before treatment (P<0.05), and there was no significant difference between the two groups in the absolute value and percentage of the change of each index (P>0.05). There was no significant difference in adverse drug events between the two groups (P>0.05).

Conclusion  The efficacy and safety of original and "drug volume-based purchasing" atorvastatin in patients with acute coronary syndrome is consistent.

1.Tang M, He J, Chen M, et al. "4+7" city drug volume-based purchasing and using pilot program in China and its impact[J]. Drug Discov Ther, 2019, 13(6): 365-369. DOI: 10.5582/ddt.2019.01093.

2.上海市医药集中招标采购事务管理所. 关于公布联盟地区药品集中采购中选结果的通知[Z]. 2019.

3.上海市医药集中招标采购事务管理所. 关于做好本市"4+7"城市药品集中采购中选药品采购协议到期相关工作的通知[Z]. 2020.

4.Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospec-tive meta-analysis of data from 90,056 participants in 14 randomised trials of statins[J]. Lancet, 2005, 366(9493): 1267-1278. DOI: 10.1016/S0140-6736(05)67394-1.

5.Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovas-cular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J, 2017, 38(32): 2459-2472. DOI: 10.1093/eurheartj/ehx144.

6.中国医师协会急诊医师分会, 国家卫健委能力建设与继续教育中心急诊学专家委员会, 中国医疗保健国际交流促进会急诊急救分会. 急性冠脉综合征急诊快速诊治指南(2019)[J]. 临床急诊杂志, 2019, 20(4): 253-262. DOI: 10.13201/j.issn.1009-5918.2019.04.001.

7.中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 31(10): 937-953. DOI: 10.3969/j.issn.1000- 3614.2016.10.001.

8.Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)[J]. Am J Cardiol, 1998, 81(5): 582-587. DOI: 10.1016/s0002-9149(97)00965-x.

9.杨琪, 果伟, 刘珊珊. 药品带量采购对某医院抗精神病药原研药和仿制药使用情况影响[J]. 中国医院药学杂志, 2021, 41(4): 400-403. [Yang Q, Guo W, Liu SS. Effects of procuring with target quantity on using antipsy-chotics at a hospital[J]. Chinese Journal of Hospital Pharmacy, 2021, 41(4): 400-403.] DOI: 10.13286/j.1001-5213.2021.04.13.

10.黎东生, 白雪珊. 带量采购降低药品价格的一般机理及"4+7招采模式"分析[J]. 卫生经济研究,  2019, 36(8): 10-12. [Li DS, Bai XS. The general mechanism of reducing the price of medicines by quantity purchase and the analysis of "4+7 recruitment mode"[J]. Health Economics Research, 2019, 36(8): 10-12.] http://www.cnki.com.cn/Article/CJFDTotal-WSJJ201908003.htm.

11.张弦, 陈红君. 带量采购政策下他汀类药物在上海某院的应用情况分析[J]. 中国药房, 2021, 32(2): 247-253. [Zhang X, Chen HJ. Analysis of Statins Use in a Shanghai Hospital under the Policy of Drug Quantity Purchasing[J]. China Pharmacy, 2021, 32(2): 247-253.] DOI: 10.6039/j.issn.1001-0408.2021.02.21.

12.Faubion SS, Kapoor E, Moyer AM, et al. Statin therapy: does sex matter?[J]. Menopause, 2019, 26(12): 1425-1435. DOI: 10.1097/GME.0000000000001412.